These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

634 related items for PubMed ID: 7756664

  • 21. Allogeneic versus semiallogeneic F1 bone marrow transplantation into sublethally irradiated MHC-disparate hosts. Effects on mixed lymphoid chimerism, skin graft tolerance, host survival, and alloreactivity.
    Pierce GE.
    Transplantation; 1990 Jan; 49(1):138-44. PubMed ID: 2137269
    [Abstract] [Full Text] [Related]

  • 22. Specific tolerance and immunocompetence in haploidentical, but not in completely allogeneic, canine chimeras treated with methotrexate and cyclosporine.
    Deeg HJ, Severns E, Raff RF, Sale GE, Storb R.
    Transplantation; 1987 Nov; 44(5):621-32. PubMed ID: 2961110
    [Abstract] [Full Text] [Related]

  • 23. Protection from lethal murine graft-versus-host disease without compromise of alloengraftment using transgenic donor T cells expressing a thymidine kinase suicide gene.
    Drobyski WR, Morse HC, Burns WH, Casper JT, Sandford G.
    Blood; 2001 Apr 15; 97(8):2506-13. PubMed ID: 11290616
    [Abstract] [Full Text] [Related]

  • 24. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
    Giver CR, Montes RO, Mittelstaedt S, Li JM, Jaye DL, Lonial S, Boyer MW, Waller EK.
    Biol Blood Marrow Transplant; 2003 Oct 15; 9(10):616-32. PubMed ID: 14569558
    [Abstract] [Full Text] [Related]

  • 25. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L, Lubin I, Factorowich I, Lapidot Z, Reich S, Reisner Y, Slavin S.
    J Immunol; 1994 Sep 15; 153(6):2562-7. PubMed ID: 8077666
    [Abstract] [Full Text] [Related]

  • 26. Donor gamma delta T lymphocytes promote allogeneic engraftment across the major histocompatibility barrier in mice.
    Drobyski WR, Majewski D.
    Blood; 1997 Feb 01; 89(3):1100-9. PubMed ID: 9028343
    [Abstract] [Full Text] [Related]

  • 27. Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions.
    Blazar BR, Lees CJ, Martin PJ, Noelle RJ, Kwon B, Murphy W, Taylor PA.
    J Immunol; 2000 Nov 01; 165(9):4901-9. PubMed ID: 11046015
    [Abstract] [Full Text] [Related]

  • 28. Graft-versus-host reactivity and graft-versus-leukemia effect in murine allogeneic bone marrow chimeras conditioned with total body irradiation or total lymphoid irradiation.
    Salam A, Waer M.
    Transplantation; 1996 Mar 15; 61(5):826-30. PubMed ID: 8607190
    [Abstract] [Full Text] [Related]

  • 29. New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T cells.
    Waller EK, Boyer M.
    Bone Marrow Transplant; 2000 May 15; 25 Suppl 2():S20-4. PubMed ID: 10933181
    [Abstract] [Full Text] [Related]

  • 30. Transient expansion of Mac1+Ly6-G+Ly6-C+ early myeloid cells with suppressor activity in spleens of murine radiation marrow chimeras: possible implications for the graft-versus-host and graft-versus-leukemia reactivity of donor lymphocyte infusions.
    Billiau AD, Fevery S, Rutgeerts O, Landuyt W, Waer M.
    Blood; 2003 Jul 15; 102(2):740-8. PubMed ID: 12676788
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Nonmyeloablative allogeneic bone marrow transplantation as immunotherapy for hematologic malignancies and metastatic solid tumors in preclinical models.
    Prigozhina TB, Gurevitch O, Morecki S, Yakovlev E, Elkin G, Slavin S.
    Exp Hematol; 2002 Jan 15; 30(1):89-96. PubMed ID: 11823042
    [Abstract] [Full Text] [Related]

  • 33. Graft-versus-host disease and graft-versus-leukemia effect in mice grafted with peripheral newborn blood.
    de La Selle V, Gluckman E, Bruley-Rosset M.
    Blood; 1998 Nov 15; 92(10):3968-75. PubMed ID: 9808591
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts.
    Blazar BR, Taylor PA, Smith S, Vallera DA.
    Blood; 1995 Feb 01; 85(3):842-51. PubMed ID: 7833486
    [Abstract] [Full Text] [Related]

  • 37. Significant MLR but not CTL responses against recipient antigens generated in T cells from bone marrow chimeras recovered from acute GVHD.
    Morohashi T, Ogasawara K, Kitaichi N, Iwabuchi K, Onoé K.
    Bone Marrow Transplant; 2000 Nov 01; 26(10):1069-76. PubMed ID: 11108305
    [Abstract] [Full Text] [Related]

  • 38. Mixed allogeneic reconstitution (A+B----A) to induce donor-specific transplantation tolerance. Permanent acceptance of a simultaneous donor skin graft.
    Ildstad ST, Wren SM, Oh E, Hronakes ML.
    Transplantation; 1991 Jun 01; 51(6):1262-7. PubMed ID: 1828637
    [Abstract] [Full Text] [Related]

  • 39. Donor CD4+CD25+ T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation.
    Hanash AM, Levy RB.
    Blood; 2005 Feb 15; 105(4):1828-36. PubMed ID: 15494429
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.